Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Revance Therapeutics (Newark, CA) a clinical-stage biopharmaceutical company developing botulinum toxin type A products focused on topical indications such as lateral canthal lines and hyperhidrosis, closed a $45M Series E financing. Participants include Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital […]

NovaSom (Glen Burnie, MD) a commercial-stage medical device company focused on the diagnosis of obstructive sleep apnea, closed a $35M Series F financing. Participants include Safeguard Scientifics, TPG Biotech and Quaker BioVentures.

Shield Therapeutics (United Kingdom) a clinical-stage pharmaceutical company focused on inflammatory bowel disease, closed a$12M Series A financing. Participants include Inventages Venture Capital.

Novophage (Boston, MA) a development-stage synthetic biology company focused on antimicrobial biofilms, closed a $5.7M Series A financing. Participants include Flybridge Capital Partners, Chevron Technology Ventures, Founder Collective and The Kraft Group.

Aegea Medical (Redwood City, CA) a development-stage medical device company focused on a minimally invasive treatment for abnormal uterine bleeding, closed a $13.3M Series B financing. Participants include Covidien Ventures, Alloy Ventures and Delphi Ventures.

Lotus Tissue Repair (Cambridge, MA) a development-stage biopharmaceutical company focused on dystrophic epidermolysis bullosa and other dermatologic conditions, closed a $26M Series A financing. Participants include Third Rock Ventures.

Esperance Pharmaceuticals (Baton Rouge, LA) a clinical-stage oncology and companion diagnostic company, closed a $7.5M Series B financing. Participants include Sanofi, Louisiana Fund, Themelios Ventures, Research Corporation Technologies and Advantage Capital Partners.

Cyterix Pharmacautics (San Francisco, CA) a preclinical-stage small molecule pharmaceutical company focused on oncology,closed a $9.2M Series A financing. Participants include the Column Group and SV Life Sciences.

Acetylon Pharmaceuticals (Boston, MA) a clinical-stage pharmaceuticals company focused on relapsed and relapsed-refractory multiple myeloma ,closed a $27M Series B financing. Participants have included New Spring Capital.

Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.

Ultragenyx Pharmaceutical (Novato, CA) a clinical-stage pharmaceutical company focused on inclusion body myopathy and other rare metabolic disease,vclosed a $45M Series A financing. Participants include TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures.

Trillium Therapeutics (Canada) a preclinical-stage biopharmaceutical company focused on interstitial cystitis, closed a $1M Series A financing. Participants include BDC Venture Capital.

Stabilitech (United Kingdom) a development-stage medical device company focused on a thermal stabilization technology to store vaccines and biopharmaceuticals, closed a $3.5M Series C financing. Participants were not identified.

« Previous Page« Previous Entries  Next Entries »Next Page »

to top of page...